HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Node/aorta and node/liver SUV ratios from (18)F-FDG PET/CT may improve the detection of occult mediastinal lymph node metastases in patients with non-small cell lung carcinoma.

AbstractRATIONALE AND OBJECTIVES:
Research suggests that the semiquantitative determination of nodal (18)F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET)/computed tomography (CT) may be useful for the assessment of mediastinal metastases in patients with non-small-cell lung carcinoma (NSCLC). The aim of this study was to evaluate the diagnostic ability of using different standardized uptake value (SUV) parameters in the detection of ipsilateral mediastinal (N2) disease.
MATERIALS AND METHODS:
A total of 102 patients newly diagnosed with non-small-cell lung carcinoma who underwent (18)F-FDG PET/CT before surgery and had not received prior therapy were retrospectively included. All patients underwent surgical resection of the primary tumor and mediastinal lymph node dissection. On a station-based analysis, different SUV parameters (eg, mediastinal lymph node SUV, node/aorta SUV ratio, and node/liver SUV ratio) were evaluated using the histopathologic results as the reference standard. The optimal cutoff value for each SUV parameter was determined with receiver-operating characteristic curve analysis.
RESULTS:
The areas under the receiver-operating characteristic curves were 0.674, 0.693, and 0.715 for node SUV, node/aorta SUV ratio, and node/liver SUV ratio, respectively (P < .05). With cutoff values of 3.15, 1.37, and 1.02 for node SUV, node/aorta SUV ratio, and node/liver SUV ratio, respectively, the sensitivity of (18)F-FDG PET/CT for N2 staging was 57.1%, 85.7%, and 71.4%, and specificity was 74.2%, 50.5%, and 61.9%.
CONCLUSIONS:
Compared to node SUV alone, the use of node/aorta and node/liver SUV ratios resulted in improved detection of N2 metastases. The two SUV parameters may potentially improve the diagnostic accuracy of (18)F-FDG PET/CT for the diagnosis of N2 disease in patients with non-small-cell lung carcinoma.
AuthorsWen-Han Kuo, Yi-Cheng Wu, Ching-Yang Wu, Kung-Chu Ho, Pin-Hsiu Chiu, Chih-Wei Wang, Chee-Jen Chang, Chih-Teng Yu, Tzu-Chen Yen, Chieh Lin
JournalAcademic radiology (Acad Radiol) Vol. 19 Issue 6 Pg. 685-92 (Jun 2012) ISSN: 1878-4046 [Electronic] United States
PMID22459646 (Publication Type: Journal Article)
CopyrightCopyright © 2012 AUR. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Aorta (diagnostic imaging, metabolism)
  • Aortography
  • Carcinoma, Non-Small-Cell Lung (diagnosis, metabolism, secondary)
  • Female
  • Fluorodeoxyglucose F18 (pharmacokinetics)
  • Humans
  • Liver (diagnostic imaging, metabolism)
  • Lung Neoplasms (diagnosis, metabolism)
  • Lymph Nodes (diagnostic imaging, metabolism)
  • Lymphatic Metastasis
  • Male
  • Mediastinum (diagnostic imaging)
  • Middle Aged
  • Positron-Emission Tomography (methods)
  • Radiopharmaceuticals (pharmacokinetics)
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Tomography, X-Ray Computed (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: